drugset / Trial / NCT02343666
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
Phase 1
Withdrawn
Fred Hutchinson Cancer Center
National Cancer Institute (NCI) · collabNational Heart, Lung, and Blood Institute (NHLBI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This pilot phase I trial studies the side effects and best dose of human immunodeficiency virus (HIV)-resistant gene modified stem cells in treating HIV-positive patients who are undergoing first-line treatment for Hodgkin or Non-Hodgkin Lymphoma. Stem cells are collected from the patient and HIV-resistance genes are placed into the stem cells. The stem cells are then re-infused into the patient. These genetically modified stem cells may help the body make cells that are resistant to HIV infection.
Timeline
- Start
- 2016-08-15
- Primary completion
- 2020-08-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs | Cell therapy | — | Intravenous |
| Subject | carmustine | Small molecule | — | Intravenous |
| Background | O6-benzylguanine | Small molecule | — | Intravenous |
| Background | Plerixafor | Small molecule | — | Subcutaneous |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |